Epigenetic regulation by PKC-theta in human breast cancer stem cells.

人乳腺癌干细胞中 PKC-theta 的表观遗传调控。

• 批准号: nhmrc : 1105409
• 负责人: Prof David Jans
• 金额: $ 56.28万
• 依托单位: University of Canberra
• 依托单位国家: 澳大利亚
• 项目类别: Project Grants
• 财政年份: 2016
• 资助国家: 澳大利亚
• 起止时间: 2016-01-01 至 2019-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/epigenetic-regulation-pkc-stem-cells/662827
• 关键词: Epigenetic; regulation; PKC; theta; human

Treating women with advanced breast cancer is difficult, and new drugs are needed to kill the cancer stem cells that cause recurrence. We think that a newly discovered protein, PKC-?, plays an important role in recurring breast cancer and can be targeted using novel ‘epigenetic’ drugs. Here, we will use cutting-edge DNA techniques to learn how this protein controls how cancer cells grow and produce the necessary data to show that targeting this protein is likely to be effective in real patients.

治疗晚期乳腺癌的女性是困难的，需要新的药物来杀死导致复发的癌症干细胞。我们认为一种新发现的蛋白质，PKC-？，在乳腺癌复发中起着重要作用，可以使用新型“表观遗传”药物进行靶向治疗。在这里，我们将使用尖端的DNA技术来了解这种蛋白质如何控制癌细胞的生长，并产生必要的数据来表明靶向这种蛋白质在真实的患者中可能有效。